Immunoglobulin Dosage and Administration Form in CIDP and MMN
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate development of hemolysis and the variation in isokinetic
muscle strength in two groups of patients with chronic inflammatory demyelinating
polyneuropathy (CIDP) or multifocal motor neuropathy (MMN)
1. Patients shifted from 3- or 6-weekly treatment with intravenous immunoglobulin (IVIG) to
weekly treatment with subcutanoeus immunoglobulin (SCIG)
2. Patients shifted from SCIG treatment with Subcuvia® or Hizentra® to Gammanorm®.
Hypotheses
- During treatment with IVIG blood hemoglobin will fluctuate with a decline due to
infusion, whereas it will remain stable during SCIG treatment without fluctuation
- Isokinetic muscle strength in affected muscle groups is more stable during treatment
with SCIG than with IVIG
- Blood hemoglobin and changes in muscle strength is comparable during Subcuvia® or
Hizentra® and Gammanorm® treatment
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborators:
Aarhus University Hospital Octapharma Pharmazeutika Produktionsges.m.b.H.